GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » AroCell AB (OSTO:AROC) » Definitions » EV-to-FCF

AroCell AB (OSTO:AROC) EV-to-FCF : -7.16 (As of Dec. 12, 2024)


View and export this data going back to 2011. Start your Free Trial

What is AroCell AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, AroCell AB's Enterprise Value is kr46.69 Mil. AroCell AB's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was kr-6.52 Mil. Therefore, AroCell AB's EV-to-FCF for today is -7.16.

The historical rank and industry rank for AroCell AB's EV-to-FCF or its related term are showing as below:

OSTO:AROC' s EV-to-FCF Range Over the Past 10 Years
Min: -24.42   Med: -5.02   Max: 0.21
Current: -9.42

During the past 13 years, the highest EV-to-FCF of AroCell AB was 0.21. The lowest was -24.42. And the median was -5.02.

OSTO:AROC's EV-to-FCF is ranked worse than
100% of 97 companies
in the Medical Diagnostics & Research industry
Industry Median: 27.56 vs OSTO:AROC: -9.42

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-12), AroCell AB's stock price is kr0.396. AroCell AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was kr-0.230. Therefore, AroCell AB's PE Ratio (TTM) for today is At Loss.


AroCell AB EV-to-FCF Historical Data

The historical data trend for AroCell AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AroCell AB EV-to-FCF Chart

AroCell AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.23 -7.13 -3.30 -4.37 -3.39

AroCell AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.67 -3.39 -2.93 -6.16 -11.37

Competitive Comparison of AroCell AB's EV-to-FCF

For the Diagnostics & Research subindustry, AroCell AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AroCell AB's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, AroCell AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where AroCell AB's EV-to-FCF falls into.



AroCell AB EV-to-FCF Calculation

AroCell AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=46.688/-6.519
=-7.16

AroCell AB's current Enterprise Value is kr46.69 Mil.
AroCell AB's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-6.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AroCell AB  (OSTO:AROC) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

AroCell AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.396/-0.230
=At Loss

AroCell AB's share price for today is kr0.396.
AroCell AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.230.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


AroCell AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of AroCell AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AroCell AB Business Description

Traded in Other Exchanges
N/A
Address
Uppsala Business Park, Virdings alle 32 B, Uppsala, SWE, 754 50
AroCell AB is working in the area of cancer diagnostics. The company develops and commercializes markers for the determination of cell growth and apoptosis, clinically useful for prognosis, monitoring, and follow-up of cancer patients in Sweden.